BioCurex Inc. (OTCBB:BOCX) today announced results of its studies of RECAF blood test for cancer. BioCurex published that its RECAF can prevent 70% of unnecessary prostate biopsies. Results of study to be presented at the ISOBM ( International Society of Oncology and Biomarkers ) annual meeting in October, 2011.
BioCurex highlighted that potential commercial impact of these results is very significant, because this is a very specific application for which there is a pressing need and which is not currently addressed in an adequate fashion. For instance, the standard PSA blood test costs between $20 and $60 . The free-PSA blood test costs about $100 . Medicare and most health insurers typically cover PSA tests for men over 50. It is estimated that in the USA alone – which represents 5% of the worldwide population – over 1.5 million men are eligible for a free-PSA test and therefore also for a RECAF test.
Dr. Moro, BioCurex CEO stated:
“We already knew that RECAF outperformed PSA to detect early stages of prostate cancer. These new results indicate that RECAF can be successfully used together with PSA to detect prostate cancer while decreasing dramatically the number of false positives when compared to FDA approved free-PSA tests. Using this combination, we can get the organ specificity of PSA (we know the lesion is in the prostate) with the high specificity of RECAF for cancer. The result can reduce unnecessary prostate biopsies by 2/3 compared to less than 30% for free-PSA FDA approved tests. We are very excited because we have received a very positive response from a number of prospect licensees and strategic alliance partners to whom we have shown these results. This is a very substantial market niche because there are about 50 million standard PSA tests done every year and while not all of them receive a free PSA test, the cost of the latter is over $100 a piece.”
Suite 215, 7080 River Road,
Richmond, BC, V6X 1X5,
Tel: (866) 884 8669
Fax: (604) 207 9165
Antonia Haughton (604) 207 9150
BioCurex, Inc. is a biotechnology company focused on developing and commercializing products for early cancer diagnosis using a proprietary blood test based on the RECAF™ tumor marker. The test can be carried out in clinical labs or at the doctor’s office in a ‘rapid test’ format similar to pregnancy tests available in drug stores. The assay can also be used for monitoring the recurrence of cancer.